Abstract
Growth faltering in children arises from metabolic and endocrine dysfunction driven by complex interactions between poor diet, persistent infections and immunopathology. Here, we determined the progression of the plasma lipidome among Gambian children and assessed its influence on growth faltering over the first 2 years of life using panel vector autoregression modelling. We further investigated temporal associations among lipid clusters. We observed that measures of stunting, wasting and underweight significantly influence each other, and that lipid groups containing PUFA and phosphatidylcholines significantly influence growth outcomes. Linear growth was influenced by the majority of lipids, indicating a higher nutritional demand to improve height compared to weight among growth-restricted children. Our results indicate a critical role for PUFAs and choline in early life dietary interventions to combat the child growth faltering still so prevalent in low-income settings.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ISRCTN49285450
Funding Statement
The Early Nutrition and Immune Development trial (ENID; ISRCTN49285450) was jointly funded by the Medical Research Council (UK) & the Department for International Development (DFID) under the MRC/DFID Concordat agreement (MC-A760-5QX00). AK is supported by the Biotechnology and Biological Sciences Research Council (BBSRC) (BB/M027252/1 and BB/M027252/2) and also gratefully acknowledges funding from the NIHR Biomedical Research Centre Cambridge (146281).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is secondary analysis of samples obtained from a clinical trial which is approved by the joint Gambia Government / MRC The Gambia Ethics Committee (Project number SCC1126v2). The trial is monitored by an Independent Trial Monitor (ITM; Dr Karen Edmond, London School of Hygiene and Tropical Medicine) and a Data Safety Monitor (DSM; Dr Kalifa Bojang, Royal Victoria Teaching Hospital, Banjul, and MRC Unit, The Gambia).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The raw data will be published together with the manuscript. Raw data can be requested from the corresponding author.
